Orion (ORNBV) Q2 2025 earnings summary

Executive summary

• All divisions delivered strong performance in Q2 and H1 2025, with significant growth in innovative medicines, especially NubeqaⓇ sales and royalties, and robust results across branded, generics, and animal health segments.

• Achieved key regulatory milestones, including FDA approval and CHMP recommendation for darolutamide in combination with ADT for metastatic hormone-sensitive prostate cancer.

• Expanded research pipeline with new agreements, clinical trials in oncology, pain/neurology, and cardiovascular therapy, and the first biologics expected to enter clinical stage within 12–24 months.

• Major R&D and business developments included a new Cambridge R&D center, expanded collaborations, and leadership changes in key divisions.

• EasyhalerⓇ peak sales potential updated to exceed EUR 300 million annually.

Financial highlights

• Q2 2025 net sales grew 27% year-over-year to EUR 416.5 million; operating profit up 59% to EUR 104.6 million with a 25.1% margin.

• H1 2025 net sales increased 21.1% to EUR 771.0 million; operating profit up 49.8% to EUR 182.5 million; operating margin at 23.7%.

• Q2 operating cash flow per share rose to EUR 0.57 (+189.7%); H1 at EUR 1.12 (+14.1%).

• Royalties, especially from NubeqaⓇ, contributed EUR 46 million to operating profit; fixed costs increased by EUR 22 million due to planned R&D and sales investments.

• H1 2025 profit for the period was EUR 143.8 million (+50.2%); basic EPS at EUR 1.02 (+50.0%).

Outlook and guidance

• 2025 net sales expected between EUR 1,630–1,730 million; operating profit guidance set at EUR 400–500 million.

• Wide guidance range maintained due to uncertainties in NubeqaⓇ royalties, timing of R&D expenses, and potential market fluctuations.

• R&D costs projected to rise in 2025; capital expenditure to remain at 2024 levels.

• No material impact from potential U.S. pharma tariffs expected in 2025; currency fluctuations and global pricing negotiations monitored closely.

• Outlook excludes potential milestone payments and acquisitions.